• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
TechPharmaceutical Industry
Europe

AstraZeneca to buy cell therapy biotech for up to $1 billion

By
Ashleigh Furlong
Ashleigh Furlong
and
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Ashleigh Furlong
Ashleigh Furlong
and
Bloomberg
Bloomberg
Down Arrow Button Icon
March 17, 2025, 7:50 AM ET
Pascal Soriot, chief executive officer of AstraZeneca.
Pascal Soriot, chief executive officer of AstraZeneca.Cole Burston/Bloomberg via Getty Images

AstraZeneca Plc, the UK drugmaker, agreed to buy the Belgian cell therapy developer EsoBiotec for as much as $1 billion to further boost its cancer capabilities. 

Recommended Video

AstraZeneca will pay $425 million upfront and may spend up to $575 million more in development and regulatory milestones, the companies said Monday. 

As Chief Executive Officer Pascal Soriot reaps the rewards of doubling down on the competitive market for cancer medicines with blockbusters like Tagrisso, Astra is targeting the next generation of potential treatments. 

EsoBiotec’s platform has the potential to transform cell therapy, according to Astra, by empowering the immune system to attack cancers. It uses targeted viruses to engineer immune cells directly within a person’s body and could allow treatment to be delivered in minutes rather than the current standard of several weeks. 

Astra shares were little changed in early London trading, rising less than 1%. The stock has gained almost 15% so far this year. 

Current CAR-T cell therapies require doctors to harvest cells from patients, engineer them in the laboratory and then re-infuse them into a patient. While these medicines can treat certain cancers, they are expensive and difficult to manufacture, prompting drugmakers to develop medicines that could engineer cells within the body. 

EsoBiotec in January announced the start of a trial testing its experimental therapy for multiple myeloma in collaboration with China’s Shenzhen Pregene Biopharma Co. The goal is to achieve cancer-free bone marrow without requiring chemotherapy to achieve lymphodepletion as needed in traditional CAR-T treatment.

Under the terms of the deal, EsoBiotec will become a subsidiary of Astra and maintain operations in Belgium. The transaction is expected to close in the second quarter. Prior to it, Esobiotec had only raised €22 million ($24 million).

In a separate cancer deal announced Monday, Astra agreed to license a plaform to make subcutaneous drug formulations from Alteogen Inc. It didn’t disclose financial details. 

Join us at the Fortune Workplace Innovation Summit May 19–20, 2026, in Atlanta. The next era of workplace innovation is here—and the old playbook is being rewritten. At this exclusive, high-energy event, the world’s most innovative leaders will convene to explore how AI, humanity, and strategy converge to redefine, again, the future of work. Register now.
About the Authors
By Ashleigh Furlong
See full bioRight Arrow Button Icon
By Bloomberg
See full bioRight Arrow Button Icon

Latest in Tech

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

Latest in Tech

InvestingStock Options
Investor Michael Burry reveals options bet against Oracle
By Carmen Reinicke, Jeran Wittenstein and BloombergJanuary 10, 2026
15 hours ago
cappelli
AIHuman resources
AI adoption isn’t an easy way to cut jobs—or easy at all, Wharton professor says: ‘The key thing … is just how much work is involved in doing it’
By Nick LichtenbergJanuary 10, 2026
17 hours ago
MagazineNetflix
Netflix’s $82.7 billion rags-to-riches story: How the a DVD-by-mail company swallowed Hollywood
By Natalie JarveyJanuary 10, 2026
18 hours ago
Bill Gates speaks onstage at the Bloomberg Philanthropies Global Forum 2025 at The Plaza Hotel on September 24, 2025 in New York City.
AIBill Gates
Bill Gates says AI could be used as a bioterrorism weapon akin to the COVID pandemic if it falls into the wrong hands
By Eleanor PringleJanuary 9, 2026
2 days ago
shapiro
Big TechMedia
Netflix’s competition isn’t sleep anymore. Its battle against YouTube is like fighting an ‘infinite number of monkeys,’ top strategist says
By Nick LichtenbergJanuary 9, 2026
2 days ago
Bill Gates pictured in New York, May 2025.
SuccessBill Gates
Read Bill Gates’s 2026 annual letter in full
By Eleanor PringleJanuary 9, 2026
2 days ago

Most Popular

placeholder alt text
Health
Bill Gates warns the world is going 'backwards' and gives 5-year deadline before we enter a new Dark Age
By Eleanor PringleJanuary 9, 2026
2 days ago
placeholder alt text
C-Suite
Silicon Valley billionaire flies coach out of solidarity: 'If I'm going to ask my employees to do it, I need to do it, too'
By Nick LichtenbergJanuary 9, 2026
1 day ago
placeholder alt text
Success
Diary of a CEO founder says he hired someone with 'zero' work experience because she 'thanked the security guard by name' before the interview
By Emma BurleighJanuary 8, 2026
3 days ago
placeholder alt text
Economy
As U.S. debt soars past $38 trillion, the flood of corporate bonds is a growing threat to the Treasury supply
By Jason MaJanuary 10, 2026
10 hours ago
placeholder alt text
Politics
White House says it's 'reviewing protocols' after Trump seemingly violated federal policy by disclosing jobs data early
By Eva RoytburgJanuary 9, 2026
1 day ago
placeholder alt text
Economy
Gen Z is rebelling against the economy with ‘disillusionomics,’ tackling near 6-figure debt by turning life into a giant list of income streams
By Jacqueline MunisJanuary 10, 2026
19 hours ago

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.